CN110585308A - 一种金花三叶茶及其制备方法和应用 - Google Patents
一种金花三叶茶及其制备方法和应用 Download PDFInfo
- Publication number
- CN110585308A CN110585308A CN201910932370.1A CN201910932370A CN110585308A CN 110585308 A CN110585308 A CN 110585308A CN 201910932370 A CN201910932370 A CN 201910932370A CN 110585308 A CN110585308 A CN 110585308A
- Authority
- CN
- China
- Prior art keywords
- parts
- camellia
- tea
- camellia nitidissima
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001122767 Theaceae Species 0.000 title claims abstract description 27
- 240000001548 Camellia japonica Species 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 27
- 235000018597 common camellia Nutrition 0.000 title abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 56
- 210000004369 blood Anatomy 0.000 claims abstract description 56
- 239000008187 granular material Substances 0.000 claims abstract description 47
- 241001328788 Camellia nitidissima Species 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 16
- 229930195725 Mannitol Natural products 0.000 claims abstract description 16
- 239000000594 mannitol Substances 0.000 claims abstract description 16
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- 229920002472 Starch Polymers 0.000 claims abstract description 15
- 229960001855 mannitol Drugs 0.000 claims abstract description 15
- 239000008107 starch Substances 0.000 claims abstract description 15
- 235000019698 starch Nutrition 0.000 claims abstract description 15
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 12
- 229940013618 stevioside Drugs 0.000 claims abstract description 11
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019202 steviosides Nutrition 0.000 claims abstract description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 10
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 10
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 10
- 230000003647 oxidation Effects 0.000 claims abstract description 10
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000811 xylitol Substances 0.000 claims abstract description 9
- 235000010447 xylitol Nutrition 0.000 claims abstract description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 9
- 229960002675 xylitol Drugs 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 8
- 229920001353 Dextrin Polymers 0.000 claims abstract description 8
- 239000004375 Dextrin Substances 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 241001365741 Lithocarpus litseifolius Species 0.000 claims abstract description 8
- 240000000249 Morus alba Species 0.000 claims abstract description 8
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 8
- 235000019425 dextrin Nutrition 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 229960001375 lactose Drugs 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 38
- 239000008103 glucose Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 22
- 238000000605 extraction Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 239000002131 composite material Substances 0.000 description 13
- 230000001603 reducing effect Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000003345 hyperglycaemic effect Effects 0.000 description 10
- 238000000465 moulding Methods 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 239000003973 paint Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000012943 hotmelt Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 241001657422 Camellia petelotii Species 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000013386 optimize process Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000209507 Camellia Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000526900 Camellia oleifera Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241001018563 Nekemias grossedentata Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提出了一种金花三叶茶,包括金花茶叶10‑40份、藤茶5‑30份、荷叶5‑30份、桑叶7‑20份、木姜叶柯5‑20份。还包括必须的辅料,所述辅料选自糊精、可溶性淀粉、糖粉、乳糖、甘露醇、木糖醇、甜菊苷中的一种或几种。本发明制得的金花三叶茶组合物及其颗粒具有良好的抗氧化、降血糖。
Description
技术领域
本发明涉及降血糖技术领域,具体涉及一种金花三叶茶及其制备方法和应用。
背景技术
当血糖值高过规定的水平时就会形成高血糖症。高血糖也是通常大家所说“三高”中的一高。另外“两高”分别是高血压和高甘油三酯。当空腹(8小时内无糖及任何含糖食物摄入)血糖高于正常范围,称为高血糖,空腹血糖正常值4.0-6.1mmol/L,餐后两小时血糖高于正常范围7.8mmol/L,也可以称为高血糖,高血糖不是一种疾病的诊断,只是一种血糖监测结果的判定,血糖监测是一时性的结果,高血糖不完全等于糖尿病。血糖升高,尿糖增多,可引发渗透性利尿,从而引起多尿的症状;血糖升高、大量水分丢失,血渗透压也会相应升高,高血渗可刺激下丘脑的口渴中枢,从而引起口渴、多饮的症状;由于胰岛素相对或绝对的缺乏,导致体内葡萄糖不能被利用,蛋白质和脂肪消耗增多,从而引起乏力、体重减轻;为了补偿损失的糖分,维持机体活动,需要多进食;这就形成了典型的“三多一少”症状。糖尿病病人的多饮、多尿症状与病情的严重程度呈正比。另外,值得注意的是,患者吃得越多,血糖就越高,尿中失糖也越多,饥饿感也就越厉害,最终导致了恶性循环。因此,在这种情况下,以少吃为好,但不能少于每日150克主食。但如果糖尿病未缓解,病人的食欲突然降低,此时应注意是否合并感染、酮症及其他并发症。
金花茶属于山茶科、山茶属,与茶、山茶、南山茶、油茶、茶梅等为孪生姐妹,是国家一级保护植物之一。金花茶的花金黄色,耀眼夺目,仿佛涂着一层蜡,晶莹而油润,似有半透明之感。金花茶单生于叶腋,花开时,有杯状的、壶状的或碗状的,娇艳多姿,秀丽雅致。以前,人们没有见到过花色金黄的种类。1960年,中国科学工作者首次在广西防城一带发现了一种金黄色的山茶花,被命名为金花茶。国外称之为神奇的东方魔茶,被誉为“植物界大熊猫”、“茶族皇后”。金花茶属无毒级、含有400多种营养物质、无毒副作用。富含茶多糖、茶多酚、总皂甙、总黄酮、茶色素、咖啡因、蛋白质、维生素B1、B2、维生素C、维生素E、叶酸、脂肪酸、B-胡萝卜素等多种天然营养成份;金花茶含有茶氨酸、苏氨酸等几十种氨基酸,以及富含有多种对人体具有重要保健作用的天然有机锗(Ge)、硒(Se)、钼(Mo)、锌(Zn)、钒(V)等微量元素,和钾(K)、钙(Ca)、镁(Mg)等宏量元素。其所含主要功效成份及作用如下:金花茶具有明显的降血糖和尿糖作用,能有效的改善糖尿病“三高”症状。金花茶在有效降低血糖、血压的同时,可有效降低血脂,改善因高血压而引起的各种不适应症状,降低血清中胆固醇和B-脂蛋白,促进胰岛素分泌、增强免疫力、调节血流量,防止动脉粥样硬化,抗菌消炎、清热解毒、通便利尿去湿,增进肝脏代谢、防癌抑制肿瘤生长等;金花茶对降血糖、降血压、降血脂、降胆固醇,对糖尿病及其并发症有独特神奇的功效,起协同平衡调节作用。
发明内容
本发明提供一种金花三叶茶及其制备方法和应用,其目的在于,提供一种金花三叶茶,具有良好的抗氧化、降血糖等效果,制备方法简单,功效明显,且便于贮存和运输,具有良好的应用前景。
本发明提供一种金花三叶茶,包括金花茶叶10-40份、藤茶5-30份、荷叶5-30份、桑叶 7-20份、木姜叶柯5-20份。
作为本发明进一步的改进,包括金花茶叶25份、藤茶12份、荷叶10份、桑叶10份、木姜叶柯7份。
本发明进一步保护一种上述金花三叶茶颗粒,还包括必须的辅料。
作为本发明进一步的改进,所述辅料选自糊精、可溶性淀粉、糖粉、乳糖、甘露醇、木糖醇、甜菊苷中的一种或几种。
作为本发明进一步的改进,所述辅料为甘露醇、可溶性淀粉、甜菊苷。
本发明进一步保护一种上述金花三叶茶颗粒的制备方法,包括以下步骤:
S1.干膏粉制备:按处方比例称取药材,加10-20倍量水提取1-3次,每次1-2h,合并提取液,浓缩,80℃下减压干燥,粉碎,过80目筛,即得;
S2.颗粒制备工艺:精密称取干膏粉和辅料,充分混匀,喷以适量乙醇作为润湿剂,制成软材后以12目筛制粒,60-80℃常压干燥3h,24目筛整粒,得到金花三叶茶颗粒
作为本发明进一步的改进,所述干膏粉和辅料的比例为13:0.35-0.46。
作为本发明进一步的改进,所述干膏粉和甜菊苷的比例为13:0.24-0.30。
本发明进一步保护一种上述金花三叶茶在制备降血糖、抗氧化药物、保健品、功能食品中的应用。
本发明进一步保护一种上述金花三叶茶颗粒在降血糖、抗氧化方面的用途。
本发明具有如下有益效果:本发明得到一种金花三叶茶组合物及其颗粒,其提取工艺采用响应面法优化,得到最优的提取条件,并通过考察辅料添加的成型率、吸湿百分率和制粒情况、口感等条件,筛选出合理的辅料种类和剂量,制得较好的颗粒剂型,得到最佳的制备工艺;
本发明制得的金花三叶茶组合物及其颗粒具有良好的抗氧化、降血糖等效果,制备方法简单,功效明显,且便于贮存和运输,具有良好的应用前景。
附图说明
图1为实施例2中乙醇浓度和辅料比交互作用对综合评分的响应面图;
图2为实施例2中乙醇浓度和辅料比交互作用对综合评分的等高线图;
图3为实施例2中矫味剂和辅料比交互作用对综合评分的响应面图;
图4为实施例2中矫味剂和辅料比交互作用对综合评分的等高线图;
图5为实施例2中矫味剂和乙醇浓度交互作用对综合评分的响应面图;
图6为实施例2中矫味剂和乙醇浓度比交互作用对综合评分的等高线图。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整的描述,显然,所述的实施例只是本发明的部分具有代表性的实施例,而不是全部实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的其他所有实施例都属于本发明的保护范围。
实施例1提取工艺优化
1.1原料组成(重量份):金花茶叶10-40份、藤茶5-30份、荷叶5-30份、桑叶7-20份、木姜叶柯5-20份。
1.2制备方法:
按处方比例称取药材,加10-14倍量水提取1-3次,每次1-2h,合并提取液,浓缩,得到浓缩液。
1.3Box-Behnken响应面法工艺优化:
根据单因素试验结果,按照Box-BehnkenDesign实验设计原理,以总黄酮含量和得膏率计算的综合评分为响应值,选取对综合评分影响较大的药液比、提取时间和提取次数进行响应面优化,以得到最佳水提工艺。响应面实验因素水平表及编码顺序见表1。
表1响应面因素水平表及编码顺序
1.4回归模型的建立及方差分析
利用Design-Expert8.0软件对设计的17个实验点进行响应面分析,其中12个为析因点,剩余为区域中心点,重复5次用以估算实验误差[9]。响应面实验设计及结果见表2。
表2提取工艺响应面试验及结果
序号 | A药液比 | B提取时间 | C提取次数 | 综合评分(Y) |
1 | 10 | 30 | 2 | 47.24 |
2 | 14 | 30 | 2 | 54.77 |
3 | 10 | 90 | 2 | 61.87 |
4 | 14 | 90 | 2 | 85.03 |
5 | 10 | 60 | 1 | 0.00 |
6 | 14 | 60 | 1 | 15.63 |
7 | 10 | 60 | 3 | 90.16 |
8 | 14 | 60 | 3 | 95.77 |
9 | 12 | 30 | 1 | 29.53 |
10 | 12 | 90 | 1 | 12.50 |
11 | 12 | 30 | 3 | 88.39 |
12 | 12 | 90 | 3 | 95.19 |
13-17 | 12 | 60 | 2 | 68.58±0.11 |
表3提取工艺响应面实验方差分析表
由表可知,二项式拟合模型具有显著性(P<0.05),说明该模型预测与实验的实际拟合较好。方程中一次项提取次数(C)对综合评分有显著性影响(P<0.05),二次项相关系数 r(r=0.9651)值高于多元线性拟合的相关系数r(r=0.8920),二项式拟合的可信度及预测性更好,可利用该模型分析预测最佳工艺条件。
根据上述二次多项式拟合模型,分别固定一个自变量为中间值,绘制因变量综合评分随自变量变化的三维效应面图和二维等高线图,见图1-6。根据图可知提取次数(C)对因变量综合评分的影响最大,同方差分析结果一致。通过等高线图,可知提取工艺范围为:加水量 A:10-14倍,提取时间B:1.23-1.5h,提取次数C:2.28-3次。综合考虑生产成本及操作可控性,选取的最佳提取工艺应为:加水量为10,提取时间为1.2h,提取3次。
二项式拟合,结果:综合评分(R)=-287.64789+38.94006A-60.65231B +90.12438C+3.90510AB-1.25215AC+11.91497-1.54564A2-0.68737B2-12.00744C2(r2=0.9991, P<0.0001)
多元线性方程:综合评分(R)=-65.63942+3.24557A++8.66407B++38.98377C(r2=0.8920, P<0.0001)
从方程的P值看,多元线性模型的P<0.0001,二次多项式拟合模型的P<0.0001,二次多项式拟合模型和多元线性模型均具有显著性。从拟合方程的相关系数r可知二项式拟合方程的相关系数r=0.9651明显高于多元线性拟合方程的相关系数(r=0.8920),接近1,说明二次多项式方程模型能够对数据进行更好的拟合。说明该制备工艺各项指标采用二次多项式方程拟合更为恰当,故选择二次多项式拟合方程优选工艺参数,并对模型采用F检验进行方差分析,结果见上表3。
由此,得到优化的提取工艺如下:
按处方比例称取药材,加10倍量水提取3次,每次1.2h,合并提取液,浓缩,得到提取液。
实施例2成型工艺优化
2.1原料组成(重量份):金花茶叶25份、藤茶12份、荷叶10份、桑叶10份、木姜叶柯7份和辅料适量,所述辅料选自糊精、可溶性淀粉、糖粉、乳糖、甘露醇、木糖醇、甜菊苷中的一种或几种。
2.2制备方法:
S1.干膏粉制备:按处方比例称取药材,加10倍量水提取3次,每次1.2h,合并提取液,浓缩,80℃下减压干燥,粉碎,过80目筛,即得;
S2.颗粒制备工艺:精密称取干膏粉和辅料,充分混匀,喷以适量乙醇作为润湿剂,制成软材后以12目筛制粒,60-80℃常压干燥3h,24目筛整粒,得到金花三叶茶颗粒
2.3辅料种类单因素考察
经过多次预试验结果,选择干膏与辅料1:1.2(g/g)比例进行辅料筛选试验。按比例分别称取糊精、可溶性淀粉、乳糖、甘露醇、木糖醇的辅料,加入干膏中,并添加适量甜菊素作为矫味剂,以12目筛制粒,记录制粒情况,测定颗粒成型率和水分,结果见表1。
表4成型率、吸湿百分率和制粒情况测定结果表
由表可知,颗粒成型性:木糖醇>乳糖>甘露醇>淀粉>糊精,6种辅料成型率均超过 85%,即成型性均良好;在相同湿度下(相对湿度75%),颗粒的水分:甘露醇<乳糖<木糖醇<糊精<淀粉;口感:甘露醇>乳糖>木糖醇>糊精>淀粉。综合结果,考虑到生产成本以及长期服用含木糖醇辅料的食品难以消化,因此选用甘露醇与可溶性淀粉为为较好的辅料,进行混合辅料的筛选。
2.4混合辅料配比的筛选
经过多次预试验结果,分别称取干膏13.5g,按下处方表(表2),加入不同比例量的辅料,混匀后,以70%乙醇作为粘合剂,混匀制粒,以制粒情况、成型率及水分为考察指标,采用综合评价,筛选最佳的混合辅料配比。
表5混合辅料配比筛选结果
综合评分=[(成型率/最大成型率)0.3+(最小水分含量/水分含量)0.2+(口感评分/最佳口感评分)0.5]*100%
由测定结果可知,淀粉与甘露醇1:2、1:3和1:4效果较好,但考虑到其甘露醇比例较高时,制粒黏性较大,制粒较为困难,但成型率均超过85%,故考虑使用淀粉与糖粉1:2、1:2.5 和1:3比例作为混合辅料考察因素中的三个水平。
2.5粘合剂筛选
经过多次预试验结果,按淀粉与甘露醇1:2.5比例混合,分别选定55%、65%、70%、75%、 85%乙醇作为粘合剂,采用单因素试验筛选最佳粘合剂。以制粒情况、颗粒成型性作为考察指标综合评价。结果见表3。
表6粘合剂筛选
编号 | 润湿剂及粘合剂 | 成型率(%) | 制粒情况 |
1 | 55%乙醇 | 97.94 | 颗粒易黏结成块 |
2 | 65%乙醇 | 98.75 | 适中 |
3 | 70%乙醇 | 97.46 | 适中 |
4 | 75%乙醇 | 96.34 | 适中 |
5 | 85%乙醇 | 95.21 | 颗粒较散,细粉多 |
由测定结果可知,选用65%、70%、75%乙醇作为乙醇浓度考察因素的三个水平。
2.6指标及其测定方法
2.6.1成型性用颗粒的成型率测定
按《中国药典》2015年版四部通则(0982)项下的方法进行测定。取通过1号筛且不过 5号筛的为合格颗粒,颗粒合格率(%)=合格颗粒质量/颗粒总质量×100%。
2.6.2吸湿性用颗粒的百分吸湿率测定
根据参考文献[1-3],精密量取合格颗粒适量,置于恒定湿度(RH)为75%(25℃)、底部放置氯化钠过饱和溶液的干燥器中,在48小时后称量,观察其变化并称重,计算吸湿百分率。吸湿百分率(%)=(颗粒吸湿后重量-颗粒吸湿前重量)/颗粒吸湿前重量×100%。
2.6.3溶化性用颗粒的溶化时间测定
按《中国药典》2015年版四部(通则0982)项下的方法进行测定。取颗粒10g,加热水200mL后马上置磁力搅拌器上70℃恒温搅拌,并记录颗粒全部溶化时的时间,要求颗粒剂应在5min内全部溶化,允许有轻微浑浊。
2.6.4颗粒水分测定
水分测定取颗粒2g,精密称定,放入已恒重称量瓶中,再次精密称定,于105℃鼓风干燥箱中干燥6h,取出后立即置于干燥器中冷却30min,取出后立即精密称定。计算水分百分率。水分%=(颗粒干燥前质量-颗粒干燥后质量)/颗粒干燥前质量*100%
2.6.5感官评价
感官评价分级标准:味微涩,入口有较多粉质感为0~2分;味甜,微涩,入口有较少粉质感为3~5分;味甜较好,入口不够柔滑为6~8分;味甜,口感较好,入口柔滑为9~10分;
2.7考察指标的评价方法
按2015年版《中国药典》四部(通则0104)项下检查方法,选择成型性、溶化性、吸湿性、颗粒色泽均匀度、口感作为考察指标,本研究是优选保健食品的制备工艺,因此考察指标以口感(权重系数为0.4)为主,成型性、吸湿性、溶化性、颗粒色泽均匀度等四个指标权重系数分别为0.15。按以下公式评分。
综合评分=[(成型率/成型率最大值)×0.2+(吸湿百分率最小值/吸湿百分率)×0.15+(最小溶化时间/时间)×0.15+(最小水分含量/水分含量)×0.15+(口感分值/口感最佳分值) ×0.35]×100%
2.8星点设计-效应面试验
在单因素基础上,以混合辅料比例、乙醇浓度、矫味剂用量为考察因素,各因素设定3 个水平,因素水平编码见表4。称取干膏粉13份,每份约13.5g,按试验安排称取适量辅料与干膏粉混合,混匀后用相应体积分数的乙醇制软材,过12目筛制成颗粒,在烘箱中65℃烘3h,过24目筛整粒,即得。
表7因素水平表
表8星点设计-效应面试验结果
表9方差分析
方差来源 | 离差平方和 | 自由度 | 均方MS | F | P | |
模型 | 613.96 | 9 | 68.22 | 20.51 | <0.0003 | significant |
A | 14.17 | 1 | 14.17 | 4.26 | <0.0779 | |
B | 2.25 | 1 | 2.25 | 0.68 | 0.4377 | |
C | 147.15 | 1 | 147.15 | 44.25 | <0.0003 | |
AB | 1.35 | 1 | 1.35 | 0.41 | 0.5439 | |
AC | 12.76 | 1 | 12.76 | 3.84 | 0.0909 | |
BC | 5.20 | 1 | 5.20 | 1.56 | 0.2512 | |
A^2 | 333.17 | 1 | 333.17 | 100.19 | <0.0001 | |
B^2 | 78.79 | 1 | 78.79 | 23.69 | 0.0018 | |
C^2 | 0.33 | 1 | 0.33 | 0.099 | 0.7626 | |
残差 | 23.28 | 7 | 3.33 | |||
失拟项 | 23.28 | 3 | 7.76 | |||
纯误差 | 0.000 | 4 | 0.000 | |||
总差 | 637.24 | 16 |
由表9可知,二项式拟合模型具有显著性(P<0.0003),说明该模型预测与实验的实际拟合较好。方程中一次项混合辅料比例(A)、矫味剂(C)对综合评分有显著性影响(P<0.05),二次项相关系数r(r=0.9635)值高于多元线性拟合的相关系数r(r=0.2567),二项式拟合的可信度及预测性更好,可利用该模型分析预测最佳工艺条件。
根据上述二次多项式拟合模型,分别固定一个自变量为中间值,绘制因变量综合评分R 随自变量变化的三维效应面图和二维等高线图,见图1-6。根据图可知辅料用量(A)对因变量综合评分R的影响最大,同方差分析结果一致。通过等高线图,可知制剂成型工艺范围为:混合辅料比例A:0.35-0.46,B:乙醇浓度65.58-70%,矫味剂C 0.24-0.30。综合考虑生产成本及操作可控性,该试验选取的最佳制备工艺应为:混合辅料用量为0.4,乙醇浓度为66%,矫味剂为0.24g。
二项式拟合,结果:综合评分(R)=-1242.77836+1291.13645A+26.95055B +798.38145C-1.36826AB--700.48785AC-7.60243BC-1231.18611A2-0.17303B2+310.09364C2(r2=0.9635,P<0.0001)
多元线性方程:综合评分(R)=+50.32832-15.65786A+0.10611B++142.95951C(r2=0.2567,P>0.05)
从方程的P值看,二次多项式拟合模型的P<0.05,而多元线性模型的P>0.05,二次多项式具有显著性。从拟合方程的相关系数r可知二项式拟合方程的相关系数r=0.9635明显高于多元线性拟合方程的相关系数(r=0.2567),接近1,说明二次多项式方程模型能够对数据进行更好的拟合。说明该制备工艺各项指标采用二次多项式方程拟合更为恰当,故选择二次多项式拟合方程优选工艺参数,并对模型采用F检验进行方差分析,结果见上表9和图1-6。
由上可见,优化的工艺如下:
所述辅料为甘露醇、可溶性淀粉、甜菊苷。
最佳制备工艺应为:混合辅料用量为每13g干膏粉添加辅料0.4g,矫味剂甜菊苷为0.24g,乙醇浓度为66%。
测试例3降血糖实验
1.1试验动物
昆明小鼠24-28g,购自广西医科大学动物实验中心
1.2试剂与试药
链脲佐菌素(北京京丰制药集团有限公司);盐酸二甲双胍片(北京京丰制药集团有限公司,批号:180521);0.9%氯化钠注射液(回音必集团(江西)东亚制药有限公司,批号: 2018072916);柠檬酸(西陇化工股份有限公司,批号:150707);柠檬酸钠(西陇化工股份有限公司,150313)
金花三叶茶(由广西中医药大学提供):取金花茶叶、藤茶、荷叶、桑叶、木姜叶柯按比例称取10800g,加入14倍量的水,置于多功能提取罐中,加热回流1h/次,共三次。合并滤液,浓缩,连续减压干燥三天(80℃),粉碎,取干膏粉,过筛(80目),加入混合辅料甘露醇、玉米淀粉与甜菊苷适量,制得颗粒,其成型率、水分、溶化性均符合药典要求。
1.2仪器
罗氏血糖仪(A罗氏血糖健康医护公司,CCU-CHEK Active)
2.实验方法与结果
2.1方法
2.1.1建立高血糖动物模型
取成年动物,适应1天后,随机取15只动物禁食3-5小时,测空腹血糖,作为该批次动物基础血糖值。随后动物禁食24小时(自由饮水),注射链脲佐菌素(用前新鲜配制)造模,小鼠60mg/kg.BW腹腔注射,7天后动物禁食3-5小时,测血糖,血糖值10-25mmol/L为高血糖模型成功动物。
2.1.2空腹血糖试验
按高血糖模型小鼠禁食(不禁水)3小时的血糖水平进行分组,随机分为1个模型对照组、1个阳性药组(盐酸二甲双胍片0.25g/kg.BW)和3个剂量组(组间差不大于1.1mmol/L)。剂量组按人体推荐给药量的10倍、20倍、30倍,即低、中、高(5g/kg.BW、10g/kg.BW,15g/kg.BW) 三个受试样品,模型对照组给予等体重生理盐水,持续给药30天,测小鼠空腹血糖值,对比各组动物血糖值及血糖下降百分率。
2.1.3糖耐量试验
剂量分组及受试样品给予时间同2.1.1。每组动物禁食3小时,测定给葡萄糖0小时血糖值,剂量组给予不同浓度受试样品,模型对照组给予同体积溶剂,15分钟后各组经口给予葡萄糖2.0g/kg.BW,测定给葡萄糖后各组0.5、2小时的血糖值及血糖曲线下面积的变化。
2.1.4正常动物降糖实验
取成年动物小鼠40只,取按高血糖模型小鼠禁食(不禁水)3小时的血糖水平进行分组,随机分为1个对照组和3个剂量组(组间差不大于1.1mmol/L)。剂量组按人体推荐给药量的10倍、20倍、30倍,即低、中、高(5g/kg.BW、10g/kg.BW,15g/kg.BW)三个受试样品,对照组给予等体重生理盐水,持续给药30天,测小鼠空腹血糖值。
2.1.5辅助降血糖判定标准
根据《保健食品辅助降血糖功能评价方法》中的结果判定:空腹血糖和糖耐量二项指标中一项指标阳性,且对正常动物空腹血糖无影响,即可判定该受试样品辅助降血糖功能动物实验结果阳性。
2.2结果
2.2.1金花三叶茶颗粒对实验性糖尿病小鼠体重影响
与模型组比较,阳性组、金花三叶茶颗粒高、中,低剂量组,体重都有升高,差异具有显著性(p≤0.01),见表5;连续给药30d后,金花三叶茶颗粒对实验性高血糖小鼠体重影响如图1所示。从图1中可以看出,模型组、阳性组、金花三叶茶颗粒低剂量组、中剂量组和高剂量组的体重呈明显上升的趋势,但与模型组对比无显著性差异。
表10金花三叶茶颗粒对实验性糖尿病小鼠体重的影响(n=10)
与模型组比较,aP<0.01;n=10。
2.2.3金花三叶茶颗粒对高血糖小鼠空腹血糖的影响
腹腔注射链脲佐菌素后,各组动物的空腹血糖值无显著性差异,给予受试样品30d后,与模型组比较,阳性组和低、中剂量对高血糖小鼠空腹血糖具有显著降低作用(P<0.05),血糖下降百分率。
表11金花三叶茶颗粒对高血糖小鼠空腹血糖的影响(χ±SD)
与模型组比较,#P<0.05;n=10。
2.2.4金花三叶茶颗粒对高血糖模型小鼠糖耐量的影响
由表可知,与模型比较,阳性组和中、高剂量组小鼠的血糖曲线下面积均显著降低,表明受试组糖耐量指标结果为阳性。
表12金花三叶茶颗粒对高血糖模型小鼠糖耐量的影响(χ±SD)
与模型组比较,#P<0.05;n=10。
2.2.5正常动物降糖实验
由表可知,低、中、高剂量组空腹血糖变化与对照组比较无显著性差异(P>0.05),表明受试物对正常动物血糖无明显影响。
表13金花三叶茶颗粒对正常动物降糖的影响(χ±SD)
3.结论
在本项研究中金花三叶茶颗粒对高血糖小鼠空腹血糖及糖耐量的影响。依据中华人民共和国国家食品药品监督管理局《辅助降血糖功能评价方法》的标准,对金花三叶茶的降糖实验结果进行了阳性测试,表明金花三叶茶颗粒具有辅助降血糖作用。
测试例2抗氧化实验
取25-30g昆明小鼠90只,按体重随机分为9个组,即空白组、模型对照组,高、中、低剂量组(5g/kg.BW、10g/kg.BW,15g/kg.BW),阳性组(维生素E)、金花茶叶子组、藤茶组和荷叶组(采用等总质量以及相同方法制备成颗粒剂,15g/kg.BW),高、中、低剂量组给予相应浓度受试样品,空白组和模型对照组给予同体积溶剂,连续灌胃30天,末次灌胃后,模型组对照组和3个剂量组禁食16小时(过夜),然后1次性灌胃给予50%乙醇12ml/kg.BW, 6小时后处死,取肝脏(空白对照组不作处理,不禁食取材),测肝脏中SOD、GSH含量。
表14金花三叶茶颗粒对小鼠SOD、GSH的影响(χ±SD)
与模型组比较,*P<0.05,**P<0.01;n=10。
由结果可知模型对照组小鼠肝脏内SOD、GSH含量显著低于空白对照组(P<0.01),表明乙醇氧化损伤动物造模复制成功,乙醇氧化损伤模型小鼠经维E、金花三花降糖茶中、高剂量灌胃处理后,小鼠肝脏中SOD活力均极显著高于模型对照组(P<0.01)、GSH含量均显著高于模型对照组(P<0.05),表明金花三花茶提高机体的抗氧化能力。
单独采用金花茶叶子、藤茶和荷叶进行提取制备得到的颗粒,剂量为15g/kg.BW,与金花三叶茶颗粒高剂量比,小鼠肝脏中SOD活力和GSH含量均明显下降,单独使用该原料没有起到较好的抗氧化作用,三者组合制剂和具有明显协同增效的作用。
与现有技术相比,本发明制备的热熔型标线涂料添加了自制的氧化石墨烯改性二苯甲酮 UV抗紫外线剂,增强了涂料的涂覆后的力学性能,使得标线在抗拉性、弹性、延展性好,同时具有很好的防老化性能,在强紫外线照射下,标线不变形、不变色、不开裂、不老化、使用寿命长,具有较好的综合性能;本发明热熔型标线涂料添加的硫醇类固化剂使该涂料具有极好的固化的性能,在雨天以及潮湿环境下可以正常作业,适应于于南方潮湿天气以及河道、江道施工,而且其固化时间适中(约1h左右),便于施工;本发明制备的热熔型标线涂料添加的光稳定剂、增白剂等助剂含量少,成本低,对于提高涂料性能有明显的作用,制得的涂料具有良好的显白、反光的作用,能明显增强道路标志,降低交通事故的发生;本发明制备的热熔型标线涂料具有成膜固化时间短、干燥时间快、耐污性好、防尘性好、反光效果好、长期储存后粘度均匀不结皮、安全环保、寿命长等优点,具有广泛应用的前景。
本领域的技术人员在不脱离权利要求书确定的本发明的精神和范围的条件下,还可以对以上内容进行各种各样的修改。因此本发明的范围并不仅限于以上的说明,而是由权利要求书的范围来确定的。
Claims (10)
1.一种金花三叶茶,其特征在于,包括金花茶叶10-40份、藤茶5-30份、荷叶5-30份、桑叶7-20份、木姜叶柯5-20份。
2.根据权利要求1所述一种金花三叶茶,其特征在于,包括金花茶叶25份、藤茶12份、荷叶10份、桑叶10份、木姜叶柯7份。
3.一种如权利要求1所述一种金花三叶茶颗粒,其特征在于,还包括必须的辅料。
4.根据权利要求3所述一种金花三叶茶颗粒,其特征在于,所述辅料选自糊精、可溶性淀粉、糖粉、乳糖、甘露醇、木糖醇、甜菊苷中的一种或几种。
5.根据权利要求4所述一种金花三叶茶颗粒,其特征在于,所述辅料为甘露醇、可溶性淀粉、甜菊苷。
6.一种如权利要求3-5任一项权利要求所述一种金花三叶茶颗粒的制备方法,其特征在于,包括以下步骤:
S1.干膏粉制备:按处方比例称取药材,加10-20倍量水提取1-3次,每次1-2h,合并提取液,浓缩,80℃下减压干燥,粉碎,过80目筛,即得;
S2.颗粒制备工艺:精密称取干膏粉和辅料,充分混匀,喷以适量乙醇作为润湿剂,制成软材后以12目筛制粒,60-80℃常压干燥3h,24目筛整粒,得到金花三叶茶颗粒。
7.根据权利要求6所述一种金花三叶茶颗粒的制备方法,其特征在于,所述干膏粉和辅料的比例为13:0.35-0.46。
8.根据权利要求6所述一种金花三叶茶颗粒的制备方法,其特征在于,所述干膏粉和甜菊苷的比例为13∶0.24-0.30。
9.一种如权利要求1所述金花三叶茶在制备降血糖、抗氧化药物、保健品、功能食品中的应用。
10.一种如权利要求3-8任一项权利要求所述金花三叶茶颗粒在降血糖、抗氧化方面的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910932370.1A CN110585308A (zh) | 2019-09-29 | 2019-09-29 | 一种金花三叶茶及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910932370.1A CN110585308A (zh) | 2019-09-29 | 2019-09-29 | 一种金花三叶茶及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110585308A true CN110585308A (zh) | 2019-12-20 |
Family
ID=68864695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910932370.1A Withdrawn CN110585308A (zh) | 2019-09-29 | 2019-09-29 | 一种金花三叶茶及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110585308A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112945872A (zh) * | 2020-11-06 | 2021-06-11 | 广西中医药大学 | 一种金花三叶降糖茶中总黄酮含量测定方法 |
-
2019
- 2019-09-29 CN CN201910932370.1A patent/CN110585308A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112945872A (zh) * | 2020-11-06 | 2021-06-11 | 广西中医药大学 | 一种金花三叶降糖茶中总黄酮含量测定方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI331019B (en) | Therapeutic compositions | |
CN104026446A (zh) | 一种适合于高血糖人群服用的营养代餐粉及其制备方法 | |
CN102599322A (zh) | 一种适合小儿的压片糖果及其制作方法 | |
CN116096393A (zh) | 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用 | |
CN101019645B (zh) | 一种缓解疲劳和提高缺氧耐受力的保健食品及其制备方法 | |
CN113143997A (zh) | 桑提取物在制备减轻动物体重的药物中的应用 | |
CN109078132B (zh) | 一种具有降血糖或辅助降血糖的组合物及其制备方法和用途 | |
CN108523129A (zh) | 一种辅助降血糖组合物及其制备方法 | |
CN102349651A (zh) | 一种具有增强免疫力和缓解疲劳功能的保健食品及其制备方法 | |
CN103181560B (zh) | 一种具有冬季养生保健作用的保健食品及其制备方法 | |
CN107569608B (zh) | 一种用于降血糖的药物组合物 | |
CN110585308A (zh) | 一种金花三叶茶及其制备方法和应用 | |
CN110664883B (zh) | 一种具有生精作用的药物组合物 | |
CN102499366B (zh) | 调节血脂和抗疲劳的保健食品 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
CN102836334B (zh) | 一种兽用补气健脾的中药制剂 | |
CN113952419B (zh) | 一种用于慢性肾功能衰竭的药物组合物及制备方法和应用 | |
CN102552871A (zh) | 一种鞣酸蛋白酵母咀嚼片及其生产方法 | |
CN109010514A (zh) | 抗高原反应的组合物、保健品及制备方法 | |
KR20200048459A (ko) | 배 및 유자를 포함하는 기관지 질환 예방 또는 개선용 식품조성물의 제조방법 및 이에 따라 제조된 식품조성물 | |
JP2009227654A (ja) | 植物抽出物を含有するアトピー性皮膚炎改善用組成物 | |
CN108219024B (zh) | 垂丝海棠花多糖及其提取方法和在制备治疗功能性便秘药物方面的应用 | |
CN114794478A (zh) | 一种能降低血压血脂血糖的组合物及应用 | |
CN104435072B (zh) | 一种具有辅助降血糖、降血脂的提取物及其制备方法 | |
KR20060108284A (ko) | 장구채 추출물을 포함하는 간 기능 개선 및 간질환 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191220 |
|
WW01 | Invention patent application withdrawn after publication |